Post-surgical pain management and osteoarthritis treatment are two leading areas in orthopedic product development. In this interview, David Shepard of SmartTRAK speaks with Frank Lee, CEO of Pacira BioSciences, about real-world evidence from the 3,200-patient Innovations in Genicular Outcomes Registry (IGOR) registry iovera°. The discussion also explores future exploratory therapies, such as PCRX-201, an investigational localized intra-articular injection using a high-capacity adenovirus platform as a "smart thermostat" to reduce inflammation. This showcases Pacira’s innovative approach to gene therapy and potentially disease-modifying drugs, offering a broad view of regenerative pain management.
Click on the following video to learn more (20:17 min). A link to download the full transcript of the interview is also provided below.
SmartTRAK: Hi, this is David Shepard, GM and senior analyst for SmartTRAK in the orthobiologics and regenerative medicine space. It's my pleasure to be joined by Frank Lee. He is the CEO and Director for Pacira. Frank, thank you very much for taking the time with me this morning. I really appreciate it.
Frank Lee: Thanks for having me, David.
To start things off, I noticed a number of posters that you’ve presented here at the Academy, one on EXPAREL and the other one on iovera°. Can you tell us a little bit about the real-world evidence you presented here at the Academy?
FL: Thanks for that, David. We're a longstanding leader in the space of osteoarthritis and pain management. We think that in addition to the products that we have, ZILRETTA, iovera°, and EXPAREL, it's important to collect real-world evidence. Because as we all know, in clinical trials, the data, the pivotal trials are important for approval, but oftentimes, that doesn't tell the full story about the value that we bring to patients. It's with that idea that we started this IGOR registry.
I'm really pleased to say, it's really the biggest registry of its kind. It's a very high-quality registry. In fact, now we've got over 3,200 patients in this registry. It's not just for our products. I'm really proud to say that it's for all products that we capture along that patient journey. Certainly, we have information about iovera°, ZILRETTA, and EXPAREL, but we have information about lots of other products that are utilized in that setting. We're able to mine that database. We've made a substantial investment in this registry over the past several years. We're pleased to now start to present more and more analysis and data from that registry, starting with AAOS.
With AAOS, what we see is another analysis, an important analysis about ...
Want to learn more about Pacira’s innovative approach to gene therapy and potentially disease-modifying drugs? Click the button below to download the full transcript of SmartTRAK GM/Sr Analyst, Orthobio & Regen David Shepherd's interview with Pacira CEO Frank Lee.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.